McBroom & Associates LLC Sells 369 Shares of Zoetis Inc. (NYSE:ZTS)

McBroom & Associates LLC lessened its stake in Zoetis Inc. (NYSE:ZTS) by 1.0% in the fourth quarter, HoldingsChannel reports. The firm owned 37,099 shares of the company’s stock after selling 369 shares during the period. Zoetis makes up approximately 3.4% of McBroom & Associates LLC’s holdings, making the stock its 16th largest holding. McBroom & Associates LLC’s holdings in Zoetis were worth $6,045,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Stonebridge Financial Group LLC bought a new stake in Zoetis in the 4th quarter worth approximately $170,000. Summit Trail Advisors LLC grew its position in Zoetis by 46.9% in the 4th quarter. Summit Trail Advisors LLC now owns 9,269 shares of the company’s stock worth $1,510,000 after purchasing an additional 2,961 shares during the period. Arlington Trust Co LLC grew its position in Zoetis by 55.6% in the 4th quarter. Arlington Trust Co LLC now owns 1,327 shares of the company’s stock worth $216,000 after purchasing an additional 474 shares during the period. Soltis Investment Advisors LLC bought a new stake in shares of Zoetis during the 4th quarter valued at $343,000. Finally, Quilter Plc grew its position in shares of Zoetis by 17.9% during the 4th quarter. Quilter Plc now owns 353,674 shares of the company’s stock valued at $57,624,000 after acquiring an additional 53,596 shares during the period. Institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ZTS. Morgan Stanley cut their price objective on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Stifel Nicolaus cut their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Leerink Partners began coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. Finally, Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $214.00.

Zoetis Trading Up 0.2 %

Shares of Zoetis stock opened at $171.71 on Tuesday. The company has a market capitalization of $77.47 billion, a P/E ratio of 32.28, a P/E/G ratio of 2.77 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The company has a fifty day moving average of $169.26 and a 200 day moving average of $179.21. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.16%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is currently 37.59%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.